Navigation Links
Poniard Pharmaceuticals, Inc. to Present Additional Cancer Treatment Data Found Significant by TapeBeat.Com Investors
Date:1/14/2010

Oversold, Undervalued, and Poised for a Short Squeeze, Poniard Pharmaceuticals announced on January 7th, the upcoming release of new data from two phase II clinical cancer trials and multiple presentations at upcoming conferences. With an approximate 25% short position in Poniard Pharmaceuticals, the TapeBeat.Com community expects that a ‘perfect storm’ for a massive short squeeze could be brewing as other goals for the company are met.

(PRWEB) January 14, 2010 -- TapeBeat.Com, the community portal for the serious biotech investor has posted research on Poniard Pharmaceuticals, Inc., a biopharma company focused on the development and commercialization of oncology products. In recent months, the stock went down almost 70% from its high of over $9 to under $2. Recent activity on Poniard Pharmaceuticals, Inc. noticed by the TapeBeat.Com community is suggesting that the downtrend may have ended and the stock poised to rally. Savy investors seem to see a tremendous value in PARD with both concrete plans and the cash to achieve them. A 'short squeeze’ could set up around these date certain news events in January, March and June. For the full article visit TapeBeat.Com to get more details on the company's solid financial cash position, promising events in the near future, the science of the drug candidate. it’s uses, as well as a technical analysis of the stocks price movements.

1. PARD will present additional data from their Phase 2 trial using picoplatin in colorectal cancer (CRC) on January 24, 2010 at the ASCO 2010 Gastrointestinal Cancers Symposium in Orlando, Fla.

2. PARD will present data from their Phase 2 trial using picoplatin in prostate cancer on March 5th, 2010.

3. Submit SPEAR efficacy and safety data for the American Society of Clinical Oncology (ASCO) 2010 Annual Meeting taking place June 4-8, 2010 in Chicago.

4. A massive short covering rally (with a current 20% - 25% short interest) may trigger caused by upward momentum from investors.

5. Talks with the FDA for a path forward for picoplatin in small cell lung cancer (SCLC) in the first half of this year.

6. More updates from trial of an oral formulation of picoplatin, which were presented in 2009, may also occur during this time.

7. PARD fundamentals: Picoplatin avoids many of the toxicities of the widely used platinum drugs, which represent an almost $4 billion market in the US. PARD currently has about $40 million in cash to continue to develop picoplatin and break into this large market.

8. Technical rally: Technical indicators show that PARD may be oversold (note again the large short position), with a strong trend of accumulation and a bullish moving average crossover imminent.

With data from approximately 1,100 patients treated with picoplatin in lung, colorectal, prostate and ovarian cancers, there is a lot of data available to suggest the likelihood of its success in clinical trials.

Coauthor Mr. V. NUKALA: Long PARD

TapeBeat.Com is a collective of investors that combine our knowledge and abilities and present information for educational purposes. We invite you to join us. In an independent verification provided by Covestor.com, of over 30,000 private and institutional investors and securities dealers the TapeBeat portfolio has had one the HIGHEST annualized rate of return. TapeBeat.Com is not a registered financial advisor, nor a registered broker and this is not a recommendation. Any information disseminated by TapeBeat.Com is not deemed fully current or accurate, and is thus not intended to form the complete basis of any investment decision. You should always perform your own research and consult with your financial advisor before making any investment discussed. This information is not made on behalf of, or with the knowledge of the company discussed, unless specifically stated. By looking at information from TapeBeat.Com, you are agreeing to our disclaimer.

###

Read the full story at http://www.prweb.com/releases/2010PoniardPharmaceutical/01PARD/prweb3443814.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related biology technology :

1. Poniard Pharmaceuticals Announces $6.5 Million Financing
2. Poniard Pharmaceuticals Reports Third Quarter 2009 Financial Results and Provides a Corporate Update
3. Poniard Pharmaceuticals to Present at the 2009 UBS Global Life Sciences Conference
4. Poniard Pharmaceuticals Announces Pivotal Phase 3 SPEAR Trial Evaluating Picoplatin in Small Cell Lung Cancer Reaches 320th Event Target
5. Poniard Pharmaceuticals To Present at Three Upcoming Investor Conferences in September
6. Poniard Pharmaceuticals Reports Second Quarter 2009 Financial Results and Provides a Corporate Update
7. Poniard Pharmaceuticals to Host Second Quarter 2009 Financial Results Conference Call on August 4
8. Poniard Pharmaceuticals Appoints Gary A. Lyons to Board of Directors
9. Poniard Pharmaceuticals to Present at the 8th Annual Needham Life Sciences Conference
10. Poniard Pharmaceuticals Files Shelf Registration
11. Poniard Pharmaceuticals to Present at the Leerink Swann Oncology Roundtable Conference
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Poniard Pharmaceuticals, Inc.  to Present Additional Cancer Treatment Data Found Significant by TapeBeat.Com Investors 
(Date:12/8/2016)... ... December 08, 2016 , ... The ability ... optogenetics — is key to exciting advances in the study and mapping of ... projected via free-space optics stimulates small, transparent organisms and excites neurons within superficial ...
(Date:12/8/2016)... Oxford Gene Technology ... Palette an anpassbaren SureSeq™ NGS-Panels mit dem Start ... ein schnelles und kostengünstiges Studium der Varianten bei ... Erkennung von Einzel-Nukleotid-Variationen (Single Nucleotide Variation, SNV) und ... Panel und ermöglicht eine individuelle Anpassung durch die ...
(Date:12/8/2016)...  Anaconda BioMed S.L., a pre-clinical stage medical device ... neuro-thrombectomy system for the treatment of Acute Ischemic Stroke ... to join its Scientific Advisory Board (SAB). The SAB ... scientific and clinical experts to Anaconda BioMed S.L., as ... ® to its clinical phase. The SAB is ...
(Date:12/8/2016)... (PRWEB) , ... December 08, ... ... announces the commercial launch of flexible packaging for their exceptionally efficient human ... bag system extends RoosterBio’s portfolio of bioprocess media products engineered to radically ...
Breaking Biology Technology:
(Date:12/7/2016)... According to a new market research report "Emotion Detection and Recognition Market ... Application Area, End User, And Region - Global Forecast to 2021", published by ... 2016 to USD 36.07 Billion by 2021, at a Compound Annual Growth Rate ... ... MarketsandMarkets Logo ...
(Date:12/6/2016)... Valencell , the leading innovator in ... a third consecutive year of triple digit growth for ... with a 360 percent increase in companies who have ... driven by sales of its wrist and ear Benchmark™ ... technology for hearables for fitness and healthcare applications. ...
(Date:11/30/2016)... , Nov. 30, 2016 Not many of us realize that we spend ... recovery so we need to do it well. Inadequate sleep levels have been found ... pressure, stroke, diabetes, and even cancer. Maybe now is the best time ... could help them to manage their sleep quality? Continue ... ...
Breaking Biology News(10 mins):